Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937701 · ClinicalTrials.gov registry record · Phase 3
Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
NCT02937701 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 558 participants.
The verdict
NCT02937701, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
Study Summary
The main purpose of the study was to compare rheumatoid arthritis symptom improvement in participants who were given ABP 710 to those who were given infliximab, 22 weeks after starting treatment.
Interventions
- BIOLOGICAL Infliximab
- BIOLOGICAL ABP 710
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2016-10-10 |
| Est. Completion | 2018-08-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02937701
The ClinicalTrials.gov registry entry for NCT02937701 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Infliximab is the first listed.
NCT02937701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02937701 about?
NCT02937701 is a clinical study titled "Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab". The main purpose of the study was to compare rheumatoid arthritis symptom improvement in participants who were given ABP 710 to those who were given infliximab, 22 weeks after starting treatment.
What is the current status of trial NCT02937701?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2016-10-10. Estimated completion is 2018-08-13.
What interventions are being tested in trial NCT02937701?
The interventions under investigation include: Infliximab (BIOLOGICAL), ABP 710 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02937701?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.